Tadalafil
NDC Package 71455-597-10

11-digit billing NDC: 71455059710

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Tadalafil is 1.1 Erectile DysfunctionTadalafil tablets are indicated for the treatment of erectile dysfunction (ED).1.2 Benign Prostatic HyperplasiaTadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).1.3 Erectile Dysfunction and Benign Prostatic HyperplasiaTadalafil tablets are indicated for the treatment of ED and the signs and symptoms of BPH (ED/BPH).1.4 Limitation of UseIf tadalafil tablets are used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil beyond 26 weeks is unknown [see Clinical Studies ( 14.3)]. Marketed by Unyter Enterprises, this product is identified by NDC 71455-597 and is authorized under FDA application ANDA209167.

Identification & Billing

NDC Package Code
71455-597-10
Package Description
10 TABLET, FILM COATED in 1 BOTTLE
Product Code
11-Digit Billing Format
71455059710
RxNorm Crosswalk
RxCUI: 402019 - tadalafil 20 MG Oral Tablet

Clinical Specifications

Proprietary Name
Tadalafil
Dosage Form
-
Usage Information
1.1 Erectile DysfunctionTadalafil tablets are indicated for the treatment of erectile dysfunction (ED).1.2 Benign Prostatic HyperplasiaTadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).1.3 Erectile Dysfunction and Benign Prostatic HyperplasiaTadalafil tablets are indicated for the treatment of ED and the signs and symptoms of BPH (ED/BPH).1.4 Limitation of UseIf tadalafil tablets are used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil beyond 26 weeks is unknown [see Clinical Studies ( 14.3)] .

Regulatory & Marketing

Labeler Name
Unyter Enterprises
FDA Application #
ANDA209167
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-27-2019
Listing Expiration
12-31-2023
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 71455-597-10 identifies a specific commercial package of 10 tablet, film coated in 1 bottle of Tadalafil, labeled by Unyter Enterprises. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Unyter Enterprises on March 27, 2019. The current certification is valid through December 31, 2023.

How is this Unyter Enterprises product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 71455059710. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
71455-597-10
11-Digit CMS (5-4-2)
71455-0597-10

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.